Ignite Creation Date:
2025-12-24 @ 2:41 PM
Ignite Modification Date:
2025-12-26 @ 7:20 AM
Study NCT ID:
NCT00716859
Status:
COMPLETED
Last Update Posted:
2021-02-03
First Post:
2008-07-14
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.
Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
A6111137
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None